Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates--history and experimental basis.

H Fleisch1

  • 1Department of Pathophysiology, University of Berne, Switzerland.

Bone
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Introduction to bisphosphonates. History and functional mechanisms].

Der Orthopade·2007
Same author

Bisphosphonates in osteoporosis.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2003
Same author

[The water softening action of a medicinal agent. The discovery of a new drug class].

Pharmazie in unserer Zeit·2001
Same author

[Osteoclasts in the reticule. Molecular mechanisms of bisphosphonates].

Pharmazie in unserer Zeit·2001
Same author

Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease.

Seminars in oncology·2001
Same author

Can bisphosphonates be given to patients with fractures?

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2001
Same journal

Corrigendum to "The forgotten fat: A systematic review of mandibular adipose content in health and disease" [Bone 201 (2025) 117636].

Bone·2026
Same journal

Diagnosis and management of X-linked hypophosphatemia in dental practice: A scoping review.

Bone·2026
Same journal

Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis.

Bone·2026
Same journal

Bone density-based maturation of the midpalatal suture in children aged 8-15 years.

Bone·2026
Same journal

Disrupted phosphate metabolism and SIBLING/ASARM peptide accumulation underlie impaired bone mineralization in klotho-deficient (kl/kl) mice.

Bone·2026
Same journal

Linking genetic variants to bone microstructure: Histological signatures of osteogenesis imperfecta subtypes.

Bone·2026
See all related articles

Bisphosphonates, pyrophosphate analogs with a P-C-P bond, inhibit calcification and bone resorption. Their mineral-binding property is key to their therapeutic potential.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Mineral Metabolism

Background:

  • Bisphosphonates are a novel drug class characterized by a P-C-P bond, mimicking pyrophosphate.
  • Their strong affinity for hydroxyapatite crystals is a defining feature.

Observation:

  • In vitro studies demonstrate inhibition of hydroxyapatite crystal formation and dissolution.
  • In vivo, bisphosphonates impede soft tissue and, in some cases, normal calcification.
  • They exhibit potent inhibition of bone resorption.

Findings:

  • Inhibition of calcification is likely mediated by interference with calcium phosphate crystal growth.
  • The precise mechanism for bone resorption inhibition is under investigation but suggested to be cellular.
  • Bisphosphonates accumulate in mineralized tissues and are released during bone resorption, concentrating near osteoclasts.

Related Experiment Videos

Implications:

  • The efficacy of bisphosphonates in both calcification inhibition and bone resorption is structure-dependent, necessitating individual compound evaluation.
  • The shared tropism to mineral, attributed to the P-C-P group, offers avenues for developing new therapeutic agents.